RYBREVANT®▼ (amivantamab) subcutaneous demonstrates a 77 percent objective response rate in first-line treatment for patients with certain advanced forms of head and neck cancer

{
  "signal_id": "f56a2dc6-f676-a792-a50c-e21690035d3a",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-28T16:50:00+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/10/28/3390620/0/fr/rybrevant-amivantamab-sous-cutan%C3%A9-affiche-un-taux-de-r%C3%A9ponse-objective-de-77-pour-cent-en-traitement-de-premi%C3%A8re-ligne-chez-des-patients-atteints-de-certaines-formes-avanc%C3%A9es-de-ca.html",
    "title": "RYBREVANT®▼ (amivantamab) subcutaneous demonstrates a 77 percent objective response rate in first-line treatment for patients with certain advanced forms of head and neck cancer",
    "excerpt": "BEERSE, BELGIUM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today released new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study, evaluating subcutaneous RYBREVANT ® ▼ (amivantamab), in combination with a PD-1 inhibitor and fixed-duration carboplatin chemotherapy, as a first-line treatment in patients with advanced, recurrent, or metastatic head and neck squamous cell carcinoma (HNSCC), other than human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). 1 These results support the continuation of the ongoing Phase 3 pivotal OrigAMI-5 study and expand the clinical development program for subcutaneous amivantamab to patients with head and neck cancer.",
    "product": "subcutaneous RYBREVANT",
    "summary": "Johnson & Johnson released results from the Phase 1b/2 OrigAMI-4 study and expanded the clinical development of subcutaneous RYBREVANT (amivantamab) for head and neck cancer.",
    "location": "Beerse, Belgium",
    "planning": false,
    "confidence": 0.9,
    "product_data": {
      "name": "subcutaneous RYBREVANT",
      "full_text": "subcutaneous RYBREVANT ® ▼ (amivantamab)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-28T16:50:00Z",
    "location_data": [
      {
        "city": "Beerse",
        "state": "Antwerp",
        "region": "Western Europe",
        "country": "Belgium",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-28",
    "article_sentence": "These results support the continuation of the ongoing Phase 3 pivotal OrigAMI-5 study and expand the clinical development program for subcutaneous amivantamab to patients with head and neck cancer."
  }
}

curl https://signals.autobound.ai/v1/signals/f56a2dc6-f676-a792-a50c-e21690035d3a \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","limit":20}'